GABA Aminotransferase (GABAT) Assay Kit Price
Product Description: Gamma-aminobutyrate aminotransferase (GABAT) is a pyridoxal phosphate-dependent enzyme involved in the
degradation of the inhibitory neurotransmitter GABA. GABAT converts GABA and alpha-ketoglutarate to glutamate and succinic semialdehyde.
The fine balance of the GABAergic inhibitory tone in the CNS is critical for countering the excitatory pathway mediated by L-glutamate. Thus,
therapeutic targeting of the GABA system covers a broad spectrum of neurological and psychiatric disorders, and GABAT is a validated target for
epilepsy therapy because inhibition of the enzyme raises GABA concentrations in the brain. GABAT has been found in a wide variety of species
(microorganisms, plants and invertebrates) in addition to vertebrates. GABAT activity is also demonstrable in hepatic tissue in addition to brain.
GABAT deficiency is listed as a “rare disease" by the Office of Rare Disease of the NIH. The GABAT activity assay is based on sequential
transamination reaction and glutamate dehydrogenase reaction, which couples the reduction of INT to INT-formazan (molar extinction coefficient =
18/mM-cm at 492 nm), allowing for sensitive detection of GABAT enzyme activity in crude tissue samples. Assay solutions are stable for several
years if stored and handled properly.
GABAT Substrate: 5 ml, store at -80°C
TA Assay Solution: 10 ml, store at -80°C (for 200 wells)
10x Cell Lysis Solution: 25 ml, store at 4ºC
MSDS: TX-100, DMSO, INT, acetic acid, Hepes
Related kits: AST Assay, HK Enzyme Assay, GAPDH Enzyme Assay, LDH Enzyme Assay, PDH Enzyme Assay, ALT Assay
Besse et al
Personalized medicine approach confirms a milder case of ABAT deficiency
Molecular Brain 9: 93, 2016
Zhao et al
High methylation of the 4-aminobutyrate aminotransferase gene predicts a poor prognosis in patients with myelodysplastic syndrome
International J of Oncology 54: 491-504, 2019
Biomedical Research Service
& Clinical Application